By Suherman Candra Maholtra 
In a landmark study set to be presented at the American College of Cardiology’s Annual Scientific Session (ACC.26), researchers have revealed that the shingles vaccine offers a profound secondary benefit for those already suffering from heart disease. The findings indicate that patients with established cardiovascular issues who received a shingles vaccination experienced nearly half the rate of serious heart-related events within one year compared to their unvaccinated counterparts. This discovery adds a significant new dimension to preventive cardiology, suggesting that a routine immunization typically associated with dermatological health may serve as a powerful tool in the fight against heart attacks and strokes.
The research, led by Dr. Robert Nguyen, a resident physician at the University of California, Riverside, scrutinized the medical records of over 246,000 adults across the United States. All participants in the study had been diagnosed with atherosclerotic cardiovascular disease (ASCVD), a condition characterized by the dangerous buildup of fats, cholesterol, and other substances in and on the artery walls. By focusing on this specific high-risk demographic, the study highlights how the protective effects of the vaccine may be amplified in individuals whose vascular systems are already compromised.
Methodology and the Scope of the Research
To achieve a high degree of statistical reliability, the research team utilized TriNetX, a global health research network that provides access to anonymized electronic health records from millions of patients across various healthcare organizations. The study focused on a cohort of adults aged 50 and older—the primary demographic for shingles vaccination—who were diagnosed with atherosclerotic disease between 2018 and 2025.
The analysis included a total of 246,822 individuals. To ensure the results were not skewed by external factors, the researchers employed a rigorous matching process. They created two equal groups of 123,411 people: one group that had received at least one dose of either the Shingrix (recombinant) or Zostavax (live-attenuated) shingles vaccine, and a control group that had not been vaccinated. The groups were meticulously balanced to ensure they were similar in terms of age, gender, race, and the presence of other health conditions such as diabetes, hypertension, and obesity.
The researchers tracked cardiovascular outcomes starting one month after the vaccination date and continuing for a full year. By excluding the first month, the team aimed to eliminate any short-term inflammatory responses to the vaccine itself, focusing instead on the sustained protective period.
Substantial Reductions in Mortality and Cardiac Events
The results of the data analysis were striking across every metric measured. The most significant finding was that vaccinated individuals were 46% less likely to experience a major adverse cardiac event (MACE)—a composite endpoint that includes heart attack, stroke, and cardiovascular death. Even more noteworthy was the 66% reduction in all-cause mortality among the vaccinated group.
Specific breakdowns of cardiac complications further illustrated the vaccine’s impact:
- Heart Attack Risk: Reduced by 32%.
- Stroke Risk: Reduced by 25%.
- Heart Failure Hospitalization: Reduced by 25%.
Dr. Nguyen emphasized the magnitude of these figures, noting that the degree of risk reduction is comparable to some of the most effective lifestyle interventions known to modern medicine. "These reductions are substantial," Nguyen stated. "The benefits we are seeing here are on par with, or even exceed, the benefits of smoking cessation for heart health. For a patient already living with heart disease, these results provide a compelling argument for prioritizing this vaccine."
The Biological Link: Why the Shingles Vaccine Protects the Heart
The biological mechanism behind this protective effect lies in the relationship between viral infection and systemic inflammation. Shingles, or herpes zoster, is caused by the reactivation of the varicella-zoster virus (VZV), the same virus that causes chickenpox. After a person recovers from chickenpox, the virus remains dormant in the nerve tissues near the spinal cord and brain. As the immune system weakens with age or stress, the virus can reactivate, traveling along nerve fibers to the skin.
While shingles is primarily known for causing a painful, blistering rash, its impact on the vascular system is well-documented. Previous studies have shown that during a shingles outbreak, the virus can cause inflammation in the blood vessel walls, a condition known as VZV vasculopathy. This inflammation can lead to the destabilization of existing arterial plaques. When a plaque ruptures, it triggers the formation of a blood clot, which can then block blood flow to the heart (causing a heart attack) or the brain (causing a stroke).
By preventing the reactivation of the virus, the shingles vaccine effectively eliminates a significant trigger for acute inflammation and clotting. This "indirect" protection is particularly vital for patients with atherosclerosis, whose arteries are already narrowed and prone to blockage.
Contextualizing the Findings Within Public Health
The Centers for Disease Control and Prevention (CDC) currently recommends that adults aged 50 and older receive the two-dose Shingrix vaccine. The vaccine is also recommended for adults 19 and older who have weakened immune systems due to disease or therapy. While the primary goal of these recommendations has always been the prevention of shingles and its most common complication, postherpetic neuralgia (long-lasting nerve pain), this new study suggests the vaccine should be viewed through a broader public health lens.
The findings presented at ACC.26 align with a growing body of evidence regarding "vaccine pleiotropy"—the concept that vaccines can provide health benefits beyond the specific disease they target. For instance, the annual influenza vaccine has also been linked to a lower risk of heart attacks and strokes during the flu season.
The cardiovascular community has reacted with cautious optimism. If these findings are replicated in further prospective trials, the shingles vaccine could become a standard component of post-diagnostic care for heart disease patients, alongside statins, beta-blockers, and antiplatelet therapies.
Chronology of Shingles Vaccine Research
The journey to understanding the link between shingles and heart health has evolved over several decades:
- Pre-2000s: Shingles was viewed almost exclusively as a dermatological and neurological condition.
- 2006: The FDA approved Zostavax, the first shingles vaccine.
- Early 2010s: Epidemiological studies began to notice a "spike" in heart attacks and strokes in the weeks and months immediately following a shingles diagnosis.
- 2017: Shingrix was approved, demonstrating much higher efficacy (over 90%) in preventing shingles compared to Zostavax.
- 2022-2024: Multiple large-scale retrospective studies, including the current research by Dr. Nguyen, began to quantify the cardiovascular benefits of the vaccine.
- 2025: A study of generally healthy adults found a 23% reduction in cardiovascular events over an eight-year period following shingles vaccination, setting the stage for the current focus on high-risk heart disease patients.
Addressing Limitations and the "Healthy User Bias"
Despite the overwhelming data, researchers acknowledge certain limitations inherent in observational studies. One significant factor is the "healthy user bias." This refers to the possibility that individuals who proactively seek out vaccinations are also more likely to engage in other heart-healthy behaviors, such as maintaining a balanced diet, exercising regularly, and adhering to their prescribed cardiac medications.
To mitigate this, Dr. Nguyen’s team adjusted for various socioeconomic and health-related factors, including housing stability, employment status, and education levels. While these adjustments strengthen the findings, they cannot entirely replace the definitive proof provided by a randomized controlled trial (RCT).
Furthermore, the current study focused on a one-year follow-up period. While this provides a clear snapshot of the vaccine’s immediate impact, questions remain regarding how long the cardioprotective effects last and whether periodic booster shots might be necessary to maintain heart health benefits into the later decades of life.
Broader Implications for Geriatric and Preventive Care
The implications of this study extend beyond the cardiologist’s office. As the global population ages, the burden of both shingles and cardiovascular disease is expected to rise. Integrating vaccination into the management of chronic conditions could lead to a significant reduction in healthcare expenditures.
Heart failure and stroke are among the leading causes of long-term disability and hospital readmission. By reducing these events by 25% to 32%, the widespread administration of the shingles vaccine could save the healthcare system billions of dollars in acute care and rehabilitation costs.
Moreover, the study touches on a critical psychological barrier: vaccine hesitancy. Dr. Nguyen noted that in an era where medical disinformation is prevalent, providing patients with tangible, life-saving reasons to get vaccinated is essential. "Sometimes patients are unsure about whether they should get a vaccine or not," he said. "These results provide another reason for them to elect to get the vaccine. It’s not just about avoiding a rash; it’s about protecting your heart and your life."
Conclusion and Future Outlook
The presentation of this study at ACC.26 marks a pivotal moment in the intersection of infectious disease and cardiology. As researchers continue to peel back the layers of how viruses affect the vascular system, the role of immunization in chronic disease management is likely to expand.
For now, the message for clinicians and patients is clear: for those living with heart disease, the shingles vaccine is more than just a preventative measure against a painful skin condition—it is a critical intervention that could significantly lower the risk of life-threatening cardiac events. Future research will likely focus on whether other vaccines, or more frequent shingles vaccinations, could further bolster these protective effects, potentially rewriting the protocol for cardiovascular health in the 21st century.
Dr. Nguyen will officially present the full details of the study, titled "Herpes Zoster Vaccination and Risk of Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease," on Monday, March 30, at the American College of Cardiology’s Annual Scientific Session. This event is expected to draw thousands of medical professionals who will evaluate how these findings can be integrated into clinical practice to improve patient outcomes worldwide.
